Current and future directions in medical therapy for breast carcinoma: endocrine treatment (Q33970582)

30 July 2017

1 reference

title

Current and future directions in medical therapy for breast carcinoma: endocrine treatment (English)

1 reference

30 July 2017

1 reference

Pritchard KI

1

1 reference

PubMed ID

10898353

30 July 2017

language of work or name

English

0 references

publication date

1 June 2000

1 reference

30 July 2017

1 reference

30 July 2017

88

1 reference

30 July 2017

12 Suppl

1 reference

30 July 2017

3065-3072

1 reference

Anti-oestrogen Therapy for Breast Cancer: A Trial of Tamoxifen at Two Dose Levels

30 July 2017

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P

A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P

Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P

Combination Chemotherapy as an Adjuvant Treatment in Operable Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P

The Christie hospital adjuvant tamoxifen trial--status at 10 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P

Adjuvant chemoendocrine therapy in postmenopausal breast cancer: cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference. International Breast Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P

Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P

Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P

Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P

Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P

Ovarian ablation in early breast cancer: phoenix arisen?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P

Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P

Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P

Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Cli

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P

1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P

Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P

Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. 'Nolvadex' Adjuvant Trial Organisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P

Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P

Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P

The value of estrogen and progesterone receptors in the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P

A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P

A randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women: a report of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial MA.1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P

An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P

Randomized clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P

Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis--a phase III trial of the Piedmont Oncology Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P

Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P

10.1002/1097-0142(20000615)88:12+<3065::AID-CNCR25>3.0.CO;2-P

21 January 2018

Identifiers

DOI

1 reference

release_f66lq34q75gwlmue4ec44ioodm

30 July 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/f66lq34q75gwlmue4ec44ioodm

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

10898353

1 reference

PubMed ID

10898353